Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aytu Biopharma (AYTU) Finished Goods (2019 - 2025)

Historic Finished Goods for Aytu Biopharma (AYTU) over the last 7 years, with Q4 2025 value amounting to $5.6 million.

  • Aytu Biopharma's Finished Goods fell 2481.3% to $5.6 million in Q4 2025 from the same period last year, while for Dec 2025 it was $5.6 million, marking a year-over-year decrease of 2481.3%. This contributed to the annual value of $8.9 million for FY2025, which is 4533.33% up from last year.
  • Latest data reveals that Aytu Biopharma reported Finished Goods of $5.6 million as of Q4 2025, which was down 2481.3% from $7.9 million recorded in Q3 2025.
  • In the past 5 years, Aytu Biopharma's Finished Goods ranged from a high of $12.0 million in Q4 2021 and a low of $5.6 million during Q4 2025
  • Moreover, its 5-year median value for Finished Goods was $8.4 million (2022), whereas its average is $8.5 million.
  • As far as peak fluctuations go, Aytu Biopharma's Finished Goods skyrocketed by 20971.07% in 2021, and later tumbled by 3288.88% in 2022.
  • Aytu Biopharma's Finished Goods (Quarter) stood at $12.0 million in 2021, then tumbled by 30.08% to $8.4 million in 2022, then increased by 3.73% to $8.7 million in 2023, then dropped by 13.66% to $7.5 million in 2024, then fell by 24.81% to $5.6 million in 2025.
  • Its last three reported values are $5.6 million in Q4 2025, $7.9 million for Q3 2025, and $8.9 million during Q2 2025.